Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boike, S.
Right arrow Articles by Jorkasky, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boike, S.
Right arrow Articles by Jorkasky, D.
American Journal of Health-System Pharmacy, Vol 54, Issue 10, 1172-1176
Copyright © 1997 by American Society of Health-System Pharmacists

Articles

Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults

SC Boike, B Ilson, N Zariffa, and DK Jorkasky


The cardiovascular effects of granisetron given as a 30-second i.v. bolus dose and of granisetron and ondansetron given by currently recommended methods were studied. Healthy adults 18 to 50 years of age were randomly assigned to one of four treatments during each of four study periods: granisetron 10 micrograms/kg (as the hydrochloride salt) i.v. over 5 minutes, granisetron 10 micrograms/kg i.v. over 30 seconds, ondansetron 32 mg (as the hydrochloride salt) i.v. over 15 minutes, and placebo. During each study period, the researchers gave each subject three sequential injections using a double-blind, double-dummy technique. Each subject was to receive all four regimens. Two resting 12-lead electrocardiograms (ECGs) were obtained before the regimen, and one was obtained at the end of each injection and at intervals up to 24 hours after the third injection. Sitting blood pressure and pulse were measured before treatments, immediately after the end of each injection, and at intervals up to 24 hours after injection 3. Safety data were analyzed for 13 subjects, and ECG interval data for 12 of them. The mean postdose QTc interval differed significantly among regimens. There were no other significant regimen-associated differences among the four mean results for any ECG interval. The mean post-dose QTc interval for ondansetron was significantly greater than that for each of the other regimens. The drug regimens were comparable in safety and tolerability. A total of 20 adverse effects, all mild to moderate, were reported in 10 subjects. Changes in vital signs were minimal. There were no clinically important cardiovascular changes associated with the i.v. administration of granisetron 10 micrograms/kg over 30 seconds, granisetron 10 micrograms/kg over 5 minutes, or ondansetron 32 mg over 15 minutes in healthy adults.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
A. Georgy, J. Neceskas, and S. Goodin
Antiemetic care for patients with breast cancer: Focus on drug interactions and safety concerns
Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2227 - 2236.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Gentilcore, T. J. Little, C. Feinle-Bisset, M. Samsom, A. J. P. M. Smout, M. Horowitz, and K. L. Jones
Role of 5-hydroxytryptamine mechanisms in mediating the effects of small intestinal glucose on blood pressure and antropyloroduodenal motility in older subjects
Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G692 - G698.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Paul, R. Callahan, J. Au, C. H. Kindler, and C. S. Yost
Antiemetics of the 5-Hydroxytryptamine 3A Antagonist Class Inhibit Muscle Nicotinic Acetylcholine Receptors
Anesth. Analg., September 1, 2005; 101(3): 715 - 721.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Aapro
Granisetron: An Update on its Clinical Use in the Management of Nausea and Vomiting
Oncologist, November 1, 2004; 9(6): 673 - 686.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. M Navari and J. M Koeller
Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists
Ann. Pharmacother., September 1, 2003; 37(9): 1276 - 1286.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Ellis and N. Dozier
Evidence for Equivalent Electrocardiographic Changes Among the 5-HT3 Receptor Antagonists
Oncologist, April 1, 2003; 8(2): 216 - 218.
[Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
N. S. Kasinath, O. Malak, and J. Tetzlaff
Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report: [Fibrillation auriculaire causee par l'ondansetron administre pour prevenir et traiter les nausees et les vomissements postoperatoires : une etude de cas]
Can J Anesth, March 1, 2003; 50(3): 229 - 231.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Goodin and R. Cunningham
5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile
Oncologist, October 1, 2002; 7(5): 424 - 436.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. L. Keefe
The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?
Oncologist, February 1, 2002; 7(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. A. Kuryshev, A. M. Brown, L. Wang, C. R. Benedict, and D. Rampe
Interactions of the 5-Hydroxytryptamine 3 Antagonist Class of Antiemetic Drugs with Human Cardiac Ion Channels
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 614 - 620.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Society of Health-System Pharmacists.